Windlas Biotech logo

Windlas Biotech

WINDLAS NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹2,318 Cr
Volatility
High Risk
P/E Ratio
35.65
EBITDA
₹123 Cr
Return on Equity
11.44%
Debt to Equity
0.06
Book Value
₹281.35
EPS
₹28.52
52W High
₹1,181.9
52W Low
₹697.4

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

4
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 19.8%
  • Promoter holding has increased by 1.41% over last quarter.
  • Company's working capital requirements have reduced from 21.4 days to 14.4 days

Weaknesses

1
  • Company has a low return on equity of 12.8% over last 3 years.

Growth Rate

Revenue Growth
18.51% lower than 3Y
Net Income Growth
9.02% lower than 3Y
Cash Flow Change
53.88% higher than 3Y
ROE
-5.14% lower than 3Y
ROCE
-4.98% higher than 3Y
EBITDA Margin (Avg.)
-7.77% lower than 3Y

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
145
153
162
171
175
187
195
203
210
222
233
238
248
Expenses
128
134
142
149
154
164
170
177
184
194
209
213
221
Operating Profit
17
19
20
22
21
23
25
26
27
29
24
25
27
OPM %
12%
12%
13%
13%
12%
12%
13%
13%
13%
13%
10%
11%
11%
Other Income
3
3
3
4
4
5
4
5
5
4
5
4
5
Interest
0
0
0
0
0
1
1
1
1
1
1
1
2
Depreciation
3
3
3
4
6
6
7
8
7
8
8
8
7
PBT
16
18
20
23
18
20
20
21
23
24
20
20
23
Tax %
26%
23%
24%
25%
26%
23%
24%
22%
24%
25%
25%
21%
23%
Net Profit
12
14
15
17
13
16
15
16
18
18
15
16
18
EPS in Rs
5.8
6.75
7.26
8.15
6.45
7.49
7.29
7.77
8.43
8.45
7.09
7.59
8.55
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
274
315
320
288
329
428
466
513
631
760
904
942
Expenses
253
290
284
244
288
373
413
453
553
666
799
837
Operating Profit
20
25
36
44
41
55
53
60
78
94
105
105
OPM %
7%
8%
11%
15%
12%
13%
11%
12%
12%
12%
12%
11%
Other Income
1
4
5
2
1
-29
7
10
13
18
18
18
Interest
7
5
5
4
2
1
1
1
1
4
5
5
Depreciation
9
9
11
8
9
13
12
12
13
28
31
31
PBT
6
14
25
35
31
11
46
57
77
79
87
87
Tax %
20%
35%
33%
36%
27%
55%
16%
25%
25%
24%
24%
—
Net Profit
5
9
17
22
22
5
39
43
58
61
66
66
EPS in Rs
8.14
16.41
30.24
35.05
35.03
7.81
17.69
20.05
27.95
28.94
31.48
31.68
Div. Payout %
0%
0%
0%
0%
0%
0%
20%
20%
20%
20%
20%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
6
6
6
6
6
6
11
10
10
10
11
Reserves
132
141
158
188
210
193
384
392
440
495
570
Borrowings
53
62
43
30
27
32
7
5
4
33
35
Other Liabilities
90
94
93
73
100
65
89
121
172
222
291
Total Liabilities
281
304
299
297
344
296
491
529
626
760
907
Fixed Assets
56
56
58
62
68
96
91
109
179
223
213
CWIP
9
15
11
5
0
0
8
15
6
5
60
Investments
95
121
123
121
121
23
65
107
173
223
268
Other Assets
121
111
107
110
154
177
327
298
268
308
366
Total Assets
281
304
299
297
344
296
491
529
626
760
907
Figures in ₹ Crores

Cash Flow

Particulars Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
47
7
39
22
21
11
9
61
109
68
105
Investing
-62
-39
-11
-7
-9
-20
-154
-14
-92
-74
-92
Financing
38
5
-25
-8
-6
1
130
-44
-15
1
-13
Net Cash Flow
24
-27
4
7
5
-8
-15
3
2
-5
0
Free Cash Flow
35
-8
28
12
11
6
-6
-9
71
16
37
CFO/OP
249
34
122
80
84
33
34
117
163
95
115
Figures in ₹ Crores

Ratios

Particulars Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
74
70
68
79
72
68
87
83
79
80
92
Inventory Days
49
62
44
38
85
55
71
84
57
63
40
Days Payable
137
120
124
117
143
53
76
98
121
138
156
Cash Conversion Cycle
-14
13
-12
0
13
70
82
69
15
6
-24
Working Capital Days
-46
-37
2
-12
3
40
86
72
32
18
14
ROCE %
—
10%
13%
18%
14%
19%
15%
14%
18%
17%
16%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Windlas Biotech insights

47 extracted metrics + investor summaries across FY16–FY26.

Log in — free

Shareholding Pattern

FIIs2.04%Promot.63.31%Others4.36%DIIs9.84%Public20.44%As ofJun 2026

Documents

Frequently Asked Questions about Windlas Biotech

What does Windlas Biotech Ltd do?
Windlas Biotech Ltd is a leading domestic pharmaceutical formulations contract development and manufacturing organization (CDMO). The company manufactures both solid and liquid pharmaceutical dosage forms and provides a comprehensive range of CDMO services ranging from product discovery, product ...
Where is Windlas Biotech Ltd (WINDLAS) listed?
Windlas Biotech Ltd trades as WINDLAS on the NSE and under code 543329 on the BSE.
Which sector does Windlas Biotech Ltd belong to?
Windlas Biotech Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of Windlas Biotech Ltd?
Windlas Biotech Ltd has a market capitalisation of ₹2,318 Cr, which places it in the Small Cap band.
What is the PE ratio of Windlas Biotech Ltd?
Windlas Biotech Ltd trades at a PE ratio of 35.65, on earnings per share of ₹28.52, against a book value of ₹281.35 per share.
What is the 52-week high and low of Windlas Biotech Ltd?
Over the last 52 weeks Windlas Biotech Ltd has traded between ₹697.4 and ₹1,181.9.
Does Windlas Biotech Ltd pay dividends?
Windlas Biotech Ltd has a dividend yield of 0.56%.
What is the Return on Equity (ROE) of Windlas Biotech Ltd?
Windlas Biotech Ltd reported a return on equity of 11.44%. Its debt-to-equity ratio is 0.06.

Company Information

Windlas Biotech Ltd is a leading domestic pharmaceutical formulations contract development and manufacturing organization (CDMO). The company manufactures both solid and liquid pharmaceutical dosage forms and provides a comprehensive range of CDMO services ranging from product discovery, product development, and commercial manufacturing of generic products, including complex generics.[1]

Website windlasbiotech.com
Listed 2021-08-16
Face Value ₹ 5
Issued Size 2,10,77,239

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/WINDLAS.md for Windlas Biotech Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List